Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now later-stage tilt small index

Bone Metastases: later-stage trial registry

5 of 11 indexed Bone Metastases trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 5 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Bone Metastases: 11 US clinical trials tracked, 5 recruiting.

Bone Metastases is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition bone-metastases

OPEN 5 | RECR 45% | LATE 2 | EARLY 1 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Breast Carcinoma (45% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Bone Metastases (this)45%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Bone Metastases

Bone Metastases lists 5 open slots (45% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bone Metastases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bone Metastases recruits in line with its size-band peers.

    5 of 11 indexed trials (45.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Bone Metastases research.

    M.D. Anderson Cancer Center accounts for 2 of 11 trials (18.2%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Bone Metastases trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.

  4. Bone Metastases splits between interventional and observational designs.

    5 interventional and 6 observational studies make up this index (45.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 32

Open and recent trials

11 total, page 1 of 1

RECRUITING 500 participants

Registry for Bone Metastases

Memorial Sloan Kettering Cancer Center

NCT07391410

RECRUITING Phase 3 220 participants

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

M.D. Anderson Cancer Center

NCT06065449

RECRUITING Phase 3 60 participants

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

St. Louis University

NCT03823534

RECRUITING 50 participants

Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?

Duke University

NCT03261544

RECRUITING NA 40 participants

Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases

University of Utah

NCT07202273

ACTIVE NOT RECRUITING 230 participants

Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases

Memorial Sloan Kettering Cancer Center

NCT01470105

ACTIVE NOT RECRUITING 75 participants

FDG PET/CT in Breast Cancer Bone Mets

University of Pennsylvania

NCT01996046

ACTIVE NOT RECRUITING NA 10 participants

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

City of Hope Medical Center

NCT02226276

COMPLETED 299 participants

F-18 PET Bone Scans Versus Tc-99m Bone Scans for the Diagnosis of Bone Metastases

Seattle Nuclear Medicine

NCT01254929

COMPLETED 37 participants

Bone Response in Metastatic Breast Cancer Involving Bones

M.D. Anderson Cancer Center

NCT00420433

COMPLETED Phase 2 19 participants

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

University of Chicago

NCT01599793

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 2

Named interventions

Most-linked intervention names on Bone Metastases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Radiography Procedure
1 trials
Skeletal Scintigraphy Procedure
1 trials
Tc-99m bone scan Device
1 trials
F-18 PET bone scan Device
1 trials
magnetic resonance imaging Procedure
1 trials
cabozantinib Drug
1 trials
blood sampling, the SF-36 questionnaire Other
1 trials
FDG PET/CT scan Other
1 trials

US sites by state

Facility locations filed on Bone Metastases trials. A trial with sites in several states counts in each.

Texas 2 trials
New York 2 trials
Washington 1 trials
Utah 1 trials
Pennsylvania 1 trials
New Jersey 1 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bone Metastases page

11 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bone Metastases condition card totals 11 registered trials; most-linked intervention Radiography; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.